GlassScriptPhysician profile
Brittany Dixon
NPI 1063755122
$5,926.06
in general payments reported to CMS, 2019-2025
42 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.95 · 2021: $398 · 2022: $1,007 · 2023: $1,168 · 2024: $1,364 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,421.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $663.73 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $507.45 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $480.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $408.55 | 2021-2025 | Wainua, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $348.19 | 2021-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $343.57 | 2022-2024 | Optimizer, Optimizer |
| Merck Sharp & Dohme LLC | $265.36 | 2021-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $248.86 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Kestra Medical Technology Services, INC. | $224.28 | 2022-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.25 | 2021-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $196.93 | 2022-2025 | Onpattro, Amvuttra |
| Boston Scientific Corporation | $182.98 | 2023-2024 | Watchman Access System, Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $136.35 | 2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $135.47 | 2022-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $127.04 | 2024-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $123.28 | 2021 | |
| Esperion Therapeutics, INC. | $117.70 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $117.43 | 2024-2025 | Camzyos, Eliquis |
| Daiichi Sankyo INC. | $104.63 | 2022-2024 | Injectafer |
| Astellas Pharma US INC | $99.95 | 2020 | |
| Cvrx, INC. | $80.08 | 2023 | Barostim Neo System |
| Heartflow, INC. | $76.22 | 2025 | |
| Abbott Laboratories | $74.46 | 2021-2023 | Confirm Rx |
| Sanofi-Aventis U.S. LLC | $70.91 | 2024 | |
| Scpharmaceuticals INC. | $61.89 | 2024-2025 | |
| Vital Connect, INC | $59.08 | 2024-2025 | Vitalpatch Rtm |
| Shockwave Medical, INC | $53.32 | 2025 | |
| Amarin Pharma, INC. | $52.80 | 2021-2022 | |
| Philips North America LLC | $48.22 | 2025 | Holter |
| Abiomed | $42.24 | 2023-2025 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $30.13 | 2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $26.51 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $26.45 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $24.13 | 2025 | Attruby |
| Teleflex LLC | $22.95 | 2025 | Vascband |
| Lilly USA, LLC | $22.03 | 2025 | Zepbound |
| Inari Medical, INC. | $21.94 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.09 | 2024 | Evkeeza, Praluent |
| Irhythm Technologies, INC. | $19.42 | 2024 | Zio Monitor, Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $17.91 | 2023 | Inpefa |
| Chiesi USA, INC. | $15.64 | 2024 | Cleviprex, Kengreal |
| Idorsia Pharmaceuticals US INC | $14.32 | 2025 | Tryvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.